top of page
11 2_edited.jpg

The MYT1L Project International Family Registry

​Every voice matters.

Every story improves our understanding.

Every contribution brings us closer to improved treatments for people living with MYT1L gene differences.

What is the MYT1L Project Registry?

A Patient Registry is a secure collection of standardized information from individuals who share a medical condition. For rare diseases like MYT1L, registries are essential to improving understanding, advancing research, and ultimately shaping better care and treatments.
​
This registry is part of the IAMRARE® Program, powered by the National Organization for Rare Disorders (NORD®)—a trusted platform developed with input from the FDA, NIH, scientists, and patient advocates. It is designed to put patients and families at the center of research.

Why a Patient Registry Matters

Rare diseases present unique challenges:​

​

  • Very small patient populations

  • Delays in diagnosis due to limited awareness

  • Poor understanding of how the disease progresses

  • Few treatment pathways or proven interventions

  • Difficulty enrolling patients into research or clinical trials

 

A registry directly addresses these barriers by creating a high-quality, patient-entered, disease-specific data resource that supports researchers, clinicians, and families.

Benefits of Joining

By contributing your data, you help:

​

  • Define the natural history of MYT1L-related conditions

  • Improve understanding of how different genetic variants affect patient symptoms

  • Explore the impact of interventions such as therapies, medications, diet, and education

  • Support the development of clinical trials and accelerate treatment discovery

  • Establish standards of care informed by real-world experiences

  • Build measurable outcomes to evaluate future therapies

 

Every contribution strengthens the evidence base and brings the community closer to answers.

Governance & Oversight

The registry is overseen by:

​

  • Registry Advisory Board – composed of the registry principal investigators (Brittany Gary, MD and Elizabeth Wood, MS),  together with scientist and geneticist advisors [Juliette Coursimault (France), Jorge Granadillo (USA), Maja Hempel (Germany), and Moritz Mall (Germany)] and parent advocates [Patricia Voaden (UK), Lee Morton (UK), Tanya Dzimbowski (South Africa), Sabine Staufer (Germany) and Valérie Salomone (France)], who guide survey design, data use, and research access.

  • NORD – provides hosting, support, and compliance oversight.

  • The MYT1L Project Team – manages daily operations, registry design, and community engagement. (Brittany Gary, MD and Elizabeth Wood, MS).

 

You can be assured that patient confidentiality is protected at every stage, and all data use requests undergo careful review before being approved by the Advisory Board.

Who can participate?

  • Anyone with a pathogenic change or variant of unknown significance in the MYT1L gene

  • Parents, caregivers, or legally authorized representatives will be able to enter data on behalf of children or adults unable to do so themselves

  • Designated representatives may contribute retrospective data for deceased individuals

Our Shared Research Goals

The MYT1L Project Registry will help answer key questions:

​

  • What gene variants exist, and how common are they?

  • How do symptoms differ between individuals and across the lifespan?

  • What role do therapies, interventions, and the environment play?

  • How does early diagnosis affect long-term outcomes?

bottom of page